Janssen Global Services, LLC

Industry / private company


Location: Titusville, NJ, United States (USA) (US) US

ISNI: 0000000403894927

ROR: https://ror.org/05af73403

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies (2022) Cohen AD, Parekh S, Santomasso BD, Gallego Perez-Larraya J, Van De Donk NWCJ, Arnulf B, Mateos MV, et al. Journal article Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non–muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy (2022) Mayr R, Eckstein M, Wirtz RM, Santiago-Walker A, Baig M, Sundaram R, Carcione JC, et al. Journal article Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS) (2021) Coates LC, Gossec L, Theander E, Bergmans P, Neuhold M, Karyekar CS, Shawi M, et al. Journal article COLLAGEN TURNOVER MARKERS ASSOCIATE WITH ACTIVE PSORIATIC ARTHRITIS AND DECREASE WITH GUSELKUMAB TREATMENT (2021) Schett G, Loza MJ, Palanichamy A, Fitzgerald O, Ritchlin C, Baribaud F, Sweet K Journal article Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial (2021) Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, et al. Journal article EFFICACY AND SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY (2021) Coates LC, Gossec L, Theander E, Bergmans P, Neuhold M, Karyekar C, Shawi M, et al. Conference contribution PREFERENCES FOR TREATMENTS TO PREVENT RHEUMATOID ARTHRITIS: DISCRETE CHOICE SURVEY OF GENERAL POPULATIONS IN UNITED KINGDOM, GERMANY, AND ROMANIA (2021) Simons G, Veldwijk J, Di Santostefano R, Englbrecht M, Radawski C, Valor L, Raza K, Falahee M Journal article Treatment preferences for preventive interventions for rheumatoid arthritis: Protocol of a mixed methods case study for the Innovative Medicines Initiative PREFER project (2021) Falahee M, Simons G, Disantostefano RL, Valor Méndez L, Radawski C, Englbrecht M, Schölin Bywall K, et al. Journal article, Original article Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. (2021) Mcgonagle D, Mcinnes IB, Deodhar A, Schett G, Shawi M, Kafka S, Karyekar CS, et al. Journal article Assessment of prognostic and predictive value of FGFR alterations (FGFRa) in a real-world cohort of patients (pts) with high-risk pT1 non-muscle-invasive bladder cancer (NMIBC) (2020) Breyer J, Monga M, Mayr R, Otto W, Burger M, Eckstein M, Stöhr R, et al. Conference contribution
1 2 3 4